Corporate
News release
TopTerumo Aortic today announced the launch of the company's global endovascular registry known as TiGER (Terumo Aortic Global Endovascular Registry).
TiGER is a global, prospective, multi-arm, multi-centre registry evaluating more than 1,000 patients over a period of 5 years. The study will collect a broad range of clinical evidence on the company's comprehensive thoracic and abdominal endovascular product portfolio.
At the recent European Investigators' Meeting, the TiGER Principal Investigator, Professor Vincent Riambau, Barcelona commented, "This is a truly unique registry encompassing the complete range of endovascular solutions for the entire aorta. This will provide an unparalleled perspective on the 'real world' results of aortic endovascular procedures."
The registry will begin enrolling patients across approximately 40 sites in Europe with plans to expand into additional geographies including the United States, Japan and Latin America.
Mark Miles, Chief Commercial Officer of Terumo Aortic added, "TiGER is the industry's first global registry evaluating patients across multiple aortic pathologies using both standard and custom endovascular technologies. This reinforces our commitment to transforming the treatment of aortic disease and serves as the model for an evidence-based approach required for broad adoption of innovative device solutions."
The launch of the TiGER Registry marks an important milestone for Terumo Aortic as it continues to expand its surgical, endovascular and hybrid businesses worldwide.
About Terumo Aortic
At Terumo Aortic, our mission is to transform the treatment of aortic disease worldwide. With our comprehensive portfolio of surgical, endovascular and hybrid technologies, we enable surgeons to find the right fit for each patient anatomy.
Notes to Editors
- Terumo Corporation of Japan, a global medical device company founded in 1921 currently has over 25,000 employees worldwide.
- Terumo acquired Vascutek Ltd. in 2002 and Bolton Medical, Inc. in 2017.
- Terumo Aortic has over 1,250 employees including 850 based in Glasgow, Scotland; 330 based in Sunrise, Florida and the remaining within direct European markets.
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.